SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalIncyte (INCY)


Previous 10 
To: tuck who wrote (3196)10/21/2018 9:12:59 PM
From: Miljenko Zuanic
   of 3202
 
Dose levels, 13.5 mg for Pem v 300 mg for 087,...is whole story. To be active cancer drug, one need to be "overall toxic' at low concentration, IMO.

Share RecommendKeepReplyMark as Last Read


From: Miljenko Zuanic10/30/2018 1:21:25 PM
   of 3202
 
With ongoing carnage in bio-sector, INCY is not spared. 3Q results ( finance.yahoo.com ) are in line from expected, and that is not enough this days.

Share RecommendKeepReplyMark as Last Read


From: Miljenko Zuanic12/17/2018 11:42:41 AM
   of 3202
 
INCY is bit better than MGNX in dealing with China, still far from "brilliant":

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Miljenko Zuanic1/15/2019 10:55:36 AM
   of 3202
 
INCY calls very active on GS upgrade.

Where were they when INCY was at ~$55?

Share RecommendKeepReplyMark as Last Read


From: scaram(o)uche2/20/2019 7:41:47 AM
   of 3202
 
"Pfizer drops 10 mg dose of best-selling Xeljanz...."

endpts.com

Share RecommendKeepReplyMark as Last Read
Previous 10